Linagliptin, next drug for type 2

Boehringer Ingelheim studies on diabetes continue

INGELHEIM, Germany, September 28 / PRNewswire-Asia /-After
statement that was released this year on phase II of linagliptin,
Boehringer Ingelheim has now announced the completion of phase III of its
clinical pivotal tests with linagliptin.The company confirmed that
First results of Phase III of the Clinical Test Program
They continually support favorable efficacy and safety profile and
observed in the first linagliptin research studies, such as the
Phase II information that had shown important results as
to reducing hemoglobin A1c (HBA1C) (-0.73%, dose of 5 mg) and a profile of
Security comparable to a placebo.

Linagliptin belongs to the class of DPP-4 inhibitors, and is being
developed as a daily dose tablet orally for
Patients with type 2 diabetes. The five phase pivotal clinical trials
III included more than 4,000 patients in more than 40 countries around the world.
The main objective of these studies was to evaluate the effectiveness and profile of
linagliptin security alone and combined with common treatments against
Diabetes, even metformin, sulfonylureas and thiazolidinions (TZD).He
General program of clinical tests of linagliptin includes studies to more
long term and also studies to evaluate the safe and effective use of the
Linagliptin in patients with type 2 diabetes who have renal failure.
The complete results of phase III of the trials will be presented in
International Scientific Congresses in the following year.

Professor Anthony Barnett, medical professor and clinical director of the
Diabetes and Endocrinology Department, Heart of England NHS Foundation
Trust, Birmingham, the United Kingdom, commented "every ten seconds a
person for causes related to diabetes.The investigation must
focus on treating the disease effectively, avoiding
complications inherent to the disease, and delaying the progression of the
disease.Medications should be easy to eat, good
tolerability, low risk of drug interactions and low risk of
Collateral effects, even weight and hypoglycemia.Inhibitors
DPP-4 correspond to a more recent class of pharmacological treatments that
They seem to have many advantages compared to traditional therapies. "

"For type 2 diabetes treatments, it is important that not only
They help patients to achieve their optimal blood glucose levels, but
that ensure that the reduction remains stable and in the long term.A day of
The date, therapies have not been able to achieve constant long -term control
of glucose and, in addition, traditional combinations have shown greater
Increased collateral effects, such as hypoglycemia.In addition, it is essential
that treatments not only prevent long -term complications that
Often they are in advanced stages of the disease, but demonstrate
be a therapeutic option in those patients who have developed
Complications, such as renal failure, "said Professor Klaus Dugi, boss
of Boehringer Ingelheim Corporate Medical Affairs."The first data
of phase III of the clinical trial programs at the moment they suggest
that linagliptin will probably achieve those objectives.The current ones
Analysis of the complete data set obtained from these essays will help
evaluate the complete potential of linagliptin for the treatment of
Type 2 diabetes, "he added.

Despite the important advances in treatments, the prevalence of
Type 2 diabetes continues to increase inThe entire planet.There are approximately
250 million people with diabetes worldwide.Type 2 diabetes is
The most common, and represents almost 95% of all cases of diabetes in the
developed world.Every year, more than 3.8 million people around the world
They die from diabetes and their complications.

Traditional therapies have generally failed in compliance
With the demands of the current panorama of type 2 diabetes, and they are required
New effective and tolerable treatments.In the large facilities of
Research and Development of Boehringer Ingelheim, Center for Excellence for
Metabolic diseases, in Biberach, Germany, Development Teams
They have focused on the discovery and development of antidiabetic treatments
orals that point to new principles, such as DPP inhibition (dipeptidil
peptidase) -4 and SGLT inhibition (glucose transporters dependent on
sodium) -2.These compounds reflect the dedication of the company in terms of
Take advantage of the most advanced science to control, efficiently, diabetes
Type 2 and its frequently fatal consequences.

If you want a full version, please visit
<!
INGELHEIM.com/CORPORATE/News/press_releases/detail.asp?id=6935

   0

Thank you very much for the information Owash.: P

   0